<?xml version = '1.0' encoding = 'UTF-8'?>
<?xml-stylesheet href="/rss/styledrssBMC.css" type="text/css"?>
<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns="http://purl.org/rss/1.0/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:extra="http://www.biomedcentral.com/xml/schemas/extra/" xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/" xmlns:cc="http://web.resource.org/cc/">
	<channel rdf:about="http://www.biomedcentral.com/rss">
		<extra:info rdf:parseType="Literal">
			<html:div xmlns:html="http://www.w3.org/1999/xhtml" style="font:14px Verdana, Geneva, Arial, Helvetica, sans-serif">
				<html:span style="font-weight:bold">This is an RSS newsfeed from BioMed Central</html:span>
				<html:br/>
				<html:span style="font-size: 12px;">It is intended to be used with an RSS reader. For more information about RSS newsfeeds from BioMed Central, visit <html:br/><html:a href="http://www.biomedcentral.com/info/about/rss/" style="color:#3333CC; font-size:12px;">http://www.biomedcentral.com/info/about/rss/</html:a><html:br/>
				</html:span>
			</html:div>
		</extra:info>
		<title>Lipids in Health and Disease - Latest articles</title>
		<link>http://www.lipidworld.com</link>
		<description>The latest articles from Lipids in Health and Disease (ISSN 1476-511X) published by 
				
				BioMed Central
		</description>
        <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        <items>
            <rdf:Seq>
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/23"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/22"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/21"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/20"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/19"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/18"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/17"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/16"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/15"/>			    
            
				    <rdf:li rdf:resource="http://www.lipidworld.com/content/7/1/14"/>			    
            
            </rdf:Seq>
        </items>
    </channel>  
    
		<item rdf:about="http://www.lipidworld.com/content/7/1/23">
            
            <title>Lipoprotein Binding Preference of CD36  is Altered by Filipin Treatment</title>
			<description> The class B scavenger receptor CD36 binds multiple ligands, including oxidized and native lipoprotein species. CD36 and the related receptor SR-B1 have been localized to caveolae, domains that participate in cell signaling, transcytosis, and regulation of cellular cholesterol homeostasis. Previous work has indicated that the ligand preference of CD36 may depend on the cell type in which it is expressed. To determine if the presence or absence of caveolae is the determining factor for lipoprotein preference, we treated CHO-CD36 and C32 cells with filipin. Filipin treatment rapidly increased the binding capacity of CD36 for the native lipoproteins HDL and LDL, but did not affect the binding capacity of CD36 for oxidized LDL. Filipin treatment affected the distribution of caveolin and CD36 suggesting that the presence caveolae may modulate the ligand preference of CD36. However, its molecular mechanism how CD36 and caveolin interaction  in regulating lipoprotein transport remains to be further studied.</description>
			<link>http://www.lipidworld.com/content/7/1/23</link>
			
			 	<dc:creator>Jianshe Zhang, Wuying Chu and Ian Crandall</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:23</dc:source>
			<dc:date>2008-06-26</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-23</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>23</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-26</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/22">
            
            <title>Plasma PCSK9 levels are significantly modified by statins and fibrates in humans</title>
			<description>Background:
Proprotein convertase subtilisin kexin-like 9 (PCSK9) is a secreted glycoprotein that is transcriptionally regulated by cholesterol status. It modulates levels of circulating low density lipoprotein cholesterol (LDLC) by negatively regulating low density lipoprotein receptor (LDLR) levels. PCSK9 variants that result in 'gain of function' have been linked to autosomal dominant hypercholesterolemia, while significant protection from coronary artery disease has been documented in individuals who carry 'loss of function' PCSK9 variants. PCSK9 circulates in human plasma, and we previously reported that plasma PCSK9 is positively correlated with total cholesterol and LDLC in men.
Results:
Herein, we report the effects of two lipid-modulating therapies, namely statins and fibrates, on PCSK9 plasma levels in human subjects. We also document their effects on endogenous PCSK9 and LDLR expression in a human hepatocyte cell line, HepG2, using immunoprecipitation and immunoblot analyses. Changes in plasma PCSK9 following fenofibrate or gemfibrozil treatments (fibric acid derivatives) were inversely correlated with changes in LDLC levels (r = -0.558, p = 0.013). Atorvastatin administration (HMGCoA reductase inhibitor) significantly increased plasma PCSK9 (7.40%, p = 0.033) and these changes were inversely correlated with changes in LDLC levels (r = -0.393, p = 0.012). Immunoblot analyses of endogenous PCSK9 and LDLR expression by HepG2 cells in response to statins and fibrates showed that LDLR is more upregulated than PCSK9 by simvastatin (2.6&#215; vs 1.5&#215;, respectively at 10 &#956;M), while fenofibrate did not induce changes in either.
Conclusion:
These results suggest that in vivo (1) statins directly increase PCSK9 expression while (2) fibrates affect PCSK9 expression indirectly through its modulation of cholesterol levels and (3) that these therapies could be improved by combination with a PCSK9 inhibitor, constituting a novel hypercholesterolemic therapy, since PCSK9 was significantly upregulated by both treatments.</description>
			<link>http://www.lipidworld.com/content/7/1/22</link>
			
			 	<dc:creator>Janice Mayne, Thilina Dewpura, Angela Raymond, Marion Cousins, Anna Chaplin, Karen A Lahey, Stephen A LaHaye, Majambu Mbikay, Teik Chye Ooi and Michel Chr&#233;tien</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:22</dc:source>
			<dc:date>2008-06-11</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-22</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>22</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/21">
            
            <title>Effect of dietary fat on hepatic liver X receptor expression in P-glycoprotein deficient mice: implications for cholesterol metabolism</title>
			<description>Pgp (P-glycoprotein, MDR1, ABCB1) is an energy-dependent drug efflux pump that is a member of the ATP-binding cassette (ABC) family of proteins. Preliminary studies have reported that nonspecific inhibitors of Pgp affect synthesis and esterification of cholesterol, putatively by blocking trafficking of cholesterol from the plasma membrane to the endoplasmic reticulum, and that relative increases in Pgp within a given cell type are associated with increased accumulation of cholesterol. Several key efflux proteins involved in the cholesterol metabolic pathway are transcriptionally regulated by the nuclear hormone liver X receptor (LXR). Therefore, to examine the interplay between P-glycoprotein and the cholesterol metabolic pathway, we utilized a high fat, normal cholesterol diet to upregulate LXR&#945; without affecting dietary cholesterol. Our research has demonstrated that mice lacking in P-glycoprotein do not exhibit alterations in hepatic total cholesterol storage, circulating plasma total cholesterol levels, or total cholesterol concentration in the bile when compared to control animals on either a normal (25% calories from dietary fat) or high fat (45% calories from dietary fat) diet. However, p-glycoprotein deficient mice (Mdr1a-/-/1b-/-) exhibit increased hepatic LXR&#945; protein expression and an elevation in fecal cholesterol concentration when compared to controls.</description>
			<link>http://www.lipidworld.com/content/7/1/21</link>
			
			 	<dc:creator>Sheila J Thornton, Evelyn Wong, Stephen D Lee and Kishor M Wasan</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:21</dc:source>
			<dc:date>2008-06-11</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-21</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>21</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-06-11</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/20">
            
            <title>The effects of beta2 adrenergic receptor gene polymorphism in lipid profiles</title>
			<description>Background:
Explore the interaction between apolipoprotein E (Apo E), phospholipase A2 (PLA2) and &#946;2 adrenergic receptor (&#946;2-AR) gene polymorphisms and lipid profiles in an elderly Chinese population.
Methods:
Five hundred subjects aged 65 to 74 years were randomly selected from a community in southern Taiwan to assess the relationship between Apo E, PLA2 and &#946;2-AR gene polymorphisms and lipid profiles. Two hundred sixty-seven participants agreed to have venous blood drawn for DNA studies.
Results:
Two statistically significant differences were noted in TC and LDL-C in the Gln27Glu of the &#946;2-AR gene polymorphism (P = 0.007, P = 0.022). The low-income group had a higher HDL-C level (p = 0.076). The Gln27Glu polymorphism Glu/Glu or Gln/Glu subjects had lower TC levels compared to the Gln27Glu polymorphism Gln/Gln subjects (p = 0.092).     Lower TC levels (p = 0.082) and lower LDL-C levels (p = 0.045) in subjects with the Cys19Arg16Glu27 haplotype. Lower TC levels (p = 0.06) were also noted in subjects with the Cys19Gly 16Glu27 haplotype. On the other hand, higher VLDL-C levels (p = 0.185) and higher triglyceride (TG) levels (p = 0.190) were noted in subjects with the Cys19Gly 16Gln27 haplotype. The &#949;2 allele combined with low income had a positive effect on HDL-C (p = 0.0011), after adding the income factor in this study.
Conclusion:
When the effects of Apo E and PLA2 on lipid profiles were included in this study, &#946;2-AR gene polymorphisms reduced significant effect on lipid profiles. Similarly, low income increased effect on HDL-C. This study appeared that the results of gene-gene and gene-environment interaction, it should be considered in further studies for lipid profiles.</description>
			<link>http://www.lipidworld.com/content/7/1/20</link>
			
			 	<dc:creator>Wei-Tsung Kao, Yung-Chieh Yen and For-Wey Lung</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:20</dc:source>
			<dc:date>2008-05-21</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-20</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>20</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-21</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/19">
            
            <title>Can endogenous lipid molecules serve as predictors and prognostic markers of coronary heart disease?</title>
			<description>Dyslipidemia, and inflammatory markers: high-sensitivity C-reactive protein (hs-CRP), myeloperoxidase (MPO), lipoprotein associated phospholipase A2(Lp-PLA2), and lipid peroxides (LP) are insufficient to predict the onset, extent, and prognosis of CHD. Lipoxins (LXs), resolvins, and protectins are derived from &#969;-3 fatty acids: eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and &#969;-6 arachidonic acid in the presence of aspirin; whereas nitrolipids are formed due to the interaction between polyunsaturated fatty acids and nitric oxide (NO). LXs, resolvins, protectins, and nitrolipids are endogenous anti-inflammatory lipid molecules that inhibit production of interleukin-6 (IL-6) and tumor necrosis factor- &#945; (TNF-&#945;), suppress free radical generation, enhance NO generation; and accelerate tissue repair. Thus, beneficial actions of EPA/DHA and aspirin in CHD could be attributed to the formation of LXs, resolvins, protectins, and nitrolipids and suggest that their plasma levels aid in the prediction and prognosis of CHD.</description>
			<link>http://www.lipidworld.com/content/7/1/19</link>
			
			 	<dc:creator>Undurti N Das</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:19</dc:source>
			<dc:date>2008-05-20</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-19</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>19</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-20</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/18">
            
            <title>Characteristic comparison of triglyceride-rich remnant lipoprotein measurement between a new homogenous assay (RemL-C) and a conventional immunoseparation method (RLP-C)</title>
			<description>Background:
Increased serum remnant lipoproteins are supposed to predict cardiovascular disease in addition to increased LDL. A new homogenous assay for remnant lipoprotein-cholesterol (RemL-C) has been developed as an alternative to remnant-like particle-cholesterol (RLP-C), an immunoseparation assay, widely used for the measurement of remnant lipoprotein cholesterol.
Methods:
We evaluated the correlations and data validation between the 2 assays in 83 subjects (49 men and 34 women) without diabetes, hypertension and medications for hyperlipidemia, diabetes, and hypertension, and investigated the characteristics of remnant lipoproteins obtained by the two methods (RLP-C and RemL-C) and their relationships with IDL-cholesterol determined by our developed HPLC method.
Results:
A positive correlation was significantly found between the two methods (r = 0.853, 95%CI 0.781&#8211;0.903, p &lt; 0.0001). Bland &amp; Altman analysis revealed that RemL-C values were likely to be significantly higher than RLP-C values, particularly in samples with high levels of remnant lipoproteins. Several data dissociations between the RemL-C and RLP-C were also observed. The HPLC chromatograms show high concentrations of chylomicron cholesterol in serum samples with RemL-C level &lt; RLP-C level, but high concentrations of IDL-cholesterol in samples with RemL-C level > RLP-C level. RemL-C (r = 0.339, 95%CI 0.152&#8211;0.903; p = 0.0005) significantly correlated with IDL-cholesterol, but not RLP-C (r = 0.17, 95%CI -0.047&#8211;0.372; p = 0.1237) in all the samples (n = 83).
Conclusion:
These results suggest that there is generally a significant correlation between RemL-C and RLP-C. However, RemL-C assay is likely to reflect IDL more closely than RLP-C.</description>
			<link>http://www.lipidworld.com/content/7/1/18</link>
			
			 	<dc:creator>Hiroshi Yoshida, Hideo Kurosawa, Yuji Hirowatari, Yutaka Ogura, Katsunori Ikewaki, Ikuro Abe, Shinichi Saikawa, Kenichi Domitsu, Kumie Ito, Hidekatsu Yanai and Norio Tada</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:18</dc:source>
			<dc:date>2008-05-17</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-18</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>18</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-05-17</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/17">
            
            <title>Changes in cholesterol kinetics following sugar cane policosanol supplementation: a randomized control trial</title>
			<description>Background:
Sugar cane policosanols (SCP) have been shown to exert cholesterol-modulating properties in various studies conducted in Cuba by substantially reducing cholesterol synthesis. Independent research examining changes in cholesterol kinetics in response to SCP is limited to few studies, none of which was able to replicate findings of the original research. Moreover, no data are available on the effect of SCP on cholesterol absorption to date. The present study was undertaken to determine effects on cholesterol kinetics, namely synthesis and absorption, within hypercholesterolemic individuals consuming a SCP treatment. Twenty-one otherwise healthy hypercholesterolemic subjects participated in a randomized double-blind crossover study where they received 10 mg/day of policosanols or a placebo incorporated in margarine as an evening snack for a period of 28 days. The last week of the study phase, subjects were given 13C labelled cholesterol and deuterated water for the measurement of cholesterol absorption and synthesis respectively. Blood was collected on the first two and last five days of the trial. Cholesterol absorption and synthesis were determined by measuring red cell cholesterol 13C and deuterium enrichment, respectively.
Results:
There was no significant change in LDL cholesterol levels as compared to control. In addition, the area under the curve for red cell cholesterol 13C enrichment across 96 hours was not significantly different in the SCP group as compared to control. Similarly, no difference was observed in the fractional rate of cholesterol synthesis over the period of 24 hours between the two treatment groups.
Conclusion:
The findings of the present study fail to support previous research concerning efficacy and mechanism of action for policosanols.</description>
			<link>http://www.lipidworld.com/content/7/1/17</link>
			
			 	<dc:creator>Amira N Kassis and Peter JH Jones</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:17</dc:source>
			<dc:date>2008-04-30</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-17</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>17</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-30</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/16">
            
            <title>Effects of a high fat diet on bone of growing rats. Correlations between visceral fat, adiponectin and bone mass density</title>
			<description>In this study, we investigated some bone parameters (bone mineral content, bone mineral density, skeleton area) in growing rats fed with a high fat diet. Correlations between bone and body composition parameters are reported. Two groups of Wistar male rats (35 days old, body mass 80 &#177; 6 g) were used. Water and food were given "ad libitum" during 10 weeks. Sixteen rats (L) were given a lipid enriched diet and were compared to 16 rats (S) fed with a standard diet. Body composition and bone parameters were assessed using DXA. Results indicated that L rats had lower body mass, lean body mass; fat mass was not different between the two groups. Bone mineral content, bone mineral density, skeleton area of L rats were lower compared with S rats. Significant correlations were noted between body composition, adiponectin and bone parameters. High fat diet intake during the growing period has deleterious effects on bone parameters in rats. This study confirms in growing rats that a high fat diet is pathogenic, including bone metabolism.</description>
			<link>http://www.lipidworld.com/content/7/1/16</link>
			
			 	<dc:creator>Gerard Lac, Helian Cavalie, Edmond Ebal and Odile Michaux</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:16</dc:source>
			<dc:date>2008-04-28</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-16</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>16</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-28</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/15">
            
            <title>Synergistic effects of high fat feeding and apolipoprotein E deletion on enterocytic amyloid-beta abundance</title>
			<description>Background:
Amyloid-&#946; (A&#946;), a key protein found in amyloid plaques of subjects with Alzheimer's disease is expressed in the absorptive epithelial cells of the small intestine. Ingestion of saturated fat significantly enhances enterocytic A&#946; abundance whereas fasting abolishes expression. Apolipoprotein (apo) E has been shown to directly modulate A&#946; biogenesis in liver and neuronal cells but it's effect in enterocytes is not known. In addition, apo E modulates villi length, which may indirectly modulate A&#946; as a consequence of differences in lipid absorption. This study compared A&#946; abundance and villi length in wild-type (WT) and apo E knockout (KO) mice maintained on either a low-fat or high-fat diet. Wild-type C57BL/6J and apo E KO mice were randomised for six-months to a diet containing either 4% (w/w) unsaturated fats, or chow comprising 16% saturated fats and 1% cholesterol. Quantitative immunohistochemistry was used to assess A&#946; abundance in small intestinal enterocytes. Apo E KO mice given the low-fat diet had similar enterocytic A&#946; abundance compared to WT controls.
Results:
The saturated fat diet substantially increased enterocytic A&#946; in WT and in apo E KO mice, however the effect was greater in the latter. Villi height was significantly greater in apo E KO mice than for WT controls when given the low-fat diet. However, WT mice had comparable villi length to apo E KO when fed the saturated fat and cholesterol enriched diet. There was no effect of the high-fat diet on villi length in apo E KO mice.
Conclusion:
The findings of this study are consistent with the notion that lipid substrate availability modulates enterocytic A&#946;. Apo E may influence enterocytic lipid availability by modulating absorptive capacity.</description>
			<link>http://www.lipidworld.com/content/7/1/15</link>
			
			 	<dc:creator>Susan Galloway, Menuka MS Pallebage-Gamarallage, Ryusuke Takechi, Le Jian, Russell D Johnsen, Satvinder S Dhaliwal and John CL Mamo</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:15</dc:source>
			<dc:date>2008-04-22</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-15</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>15</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-22</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
	
		<item rdf:about="http://www.lipidworld.com/content/7/1/14">
            
            <title>Raisins and additional walking have distinct effects on plasma lipids and inflammatory cytokines</title>
			<description>Background:
Raisins are a significant source of dietary fiber and polyphenols, which may reduce cardiovascular disease (CVD) risk by affecting lipoprotein metabolism and inflammation. Walking represents a low intensity exercise intervention that may also reduce CVD risk. The purpose of this study was to determine the effects of consuming raisins, increasing steps walked, or a combination of these interventions on blood pressure, plasma lipids, glucose, insulin and inflammatory cytokines.
Results:
Thirty-four men and postmenopausal women were matched for weight and gender and randomly assigned to consume 1 cup raisins/d (RAISIN), increase the amount of steps walked/d (WALK) or a combination of both interventions (RAISINS + WALK). The subjects completed a 2 wk run-in period, followed by a 6 wk intervention. Systolic blood pressure was reduced for all subjects (P = 0.008). Plasma total cholesterol was decreased by 9.4% for all subjects (P &lt; 0.005), which was explained by a 13.7% reduction in plasma LDL cholesterol (LDL-C) (P &lt; 0.001). Plasma triglycerides (TG) concentrations were decreased by 19.5% for WALK (P &lt; 0.05 for group effect). Plasma TNF-&#945; was decreased from 3.5 ng/L to 2.1 ng/L for RAISIN (P &lt; 0.025 for time and group &#215; time effect). All subjects had a reduction in plasma sICAM-1 (P &lt; 0.01).
Conclusion:
This research shows that simple lifestyle modifications such as adding raisins to the diet or increasing steps walked have distinct beneficial effects on CVD risk.</description>
			<link>http://www.lipidworld.com/content/7/1/14</link>
			
			 	<dc:creator>Michael J Puglisi, Ushma Vaishnav, Sudeep Shrestha, Moises Torres-Gonzalez, Richard J Wood, Jeff S Volek and Maria Luz Fernandez</dc:creator>
			
			<dc:source>Lipids in Health and Disease 2008, 7:14</dc:source>
			<dc:date>2008-04-16</dc:date>
			<dc:identifier>doi:10.1186/1476-511X-7-14</dc:identifier>
			
			
							
					<prism:publicationName>Lipids in Health and Disease</prism:publicationName>
					
			
							
					<prism:issn>1476-511X</prism:issn>
					
			
							
					<prism:volume>7</prism:volume>
					
			
							
					<prism:startingPage>14</prism:startingPage>
					
			
							
					<prism:publicationDate>2008-04-16</prism:publicationDate>
					

            <cc:license rdf:resource="http://creativecommons.org/licenses/by/2.0/"/>
        </item>
		
    <cc:License rdf:about="http://creativecommons.org/licenses/by/2.0/">
         <cc:permits rdf:resource="http://creativecommons.org/ns#Reproduction"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#Distribution"/>
         <cc:permits rdf:resource="http://creativecommons.org/ns#DerivativeWorks"/>
	</cc:License>
</rdf:RDF>
